Nykode Therapeutics As (VACBF) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings, and welcome to the NICO Therapeutics Q3 2025 Financial Results Conference Calling Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. You may ask a question any time by typing it into the Ask a Question feature on your screen. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to CEO Michael Ansig. Please go ahead, sir. Thank you very much, Kevin. Also, from my side, a very warm welcome to all participants at today's Q3 report. Just to remind everybody of our forward-looking statements. Assuming you're familiar with such statements, we will move ahead. As usual, it's my pleasure to have next to me here André Fredriksen, our Chief Scientific Officer and Head of Business Development, as well as co-founder, and Gorgon, our Chief Financial Officer. Just a quick recap on our company strategy, which we announced in Q3 this year, which really demonstrates our focus on our three core assets of ISUBA, formerly known as VB1016, which is our lead asset, and we're taking it into a randomized control cloud in Phase 2, and first line hit the neck. Secondly, we retain NEO, our individualized NEO antigen therapy, with the potential to basically be a future therapy towards all cancer types. We're positioning this as the most attractive, unencumbered INT assets, ready to leverage peer data. And thirdly, our tolerance platform, which we are positioning as the best-in-class platform a tolerance platform for treatment of autoimmune diseases, potential allergy, and other diseases in that category. We're also demonstrating a disciplined approach to capital allocation, strongly capitalized with a runway that lasts into 2028, 2029. We're going to add some mor...